Kornimate/medical-research-clean huggingface dataset:
the effect of resilience psychoeducation program based on positive psychotherapy on nurses

Conditions: Psychological Stress

Summary: the effect of resilience psychoeducation program based on positive psychotherapy on nurses

based on the principles of positive psychology, positive psychotherapy integrates symptoms with strengths, resources with risks, weaknesses with values, and hopes with regret to understand the natural complexities of human experiences in a balanced way. this includes cognitive restructuring of the individual, reviewing expectations, and acquiring new goals. resilience is a person's process of adapting, resilience, or the ability to successfully cope with change/disaster against major stressors such as a trauma, a threat, a tragedy, or familial and relational distress, serious health problems, workplace and financial problems. it is stated that people with high psychological resilience are more successful in adapting to change and struggling against obstacles, and people with high psychological resilience experience less emotional exhaustion.10 possible risky situations that individuals encounter in their work life and the protective factors they have also affect their psychological resilience. it is also stated that psychological resilience is an important concept for nurses who are faced with many risk factors, especially in business life, and who have to provide professional care to patients who are in difficult situations and in need, and who have to comfort the patient.1 the effectiveness of developing and strengthening psychological resilience in coping with the stressful environment of nursing has been proven. it is stated that among the coping resources of nurses, adequate rest, self-care and social support are of great importance and that these resources are positively related to the quality of life. the aim of this research is to determine the effect of the psychological resilience psychoeducation program based on positive psychotherapy on the resilience of nurses and to determine their balanced life skills.

Eligibility criteria:
inclusion criteria: * working as a nurse at düzce university health application and research center * individuals who voluntarily agree to participate in the research will be included. exclusion criteria: * the acute phase of a psychiatric illness

Keywords: psychoeducation program nurses adult resillience scale
lunar iiib study comparing rosuvastatin and atorvastatin in subjects with acute coronary syndromes

Conditions: Acute Coronary Syndromes

Summary: comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes


Eligibility criteria:
inclusion criteria: * non-st segment elevation acs and st segment elevation acs who receive optimal reperfusion therapy exclusion criteria: * previous q-wave infarct within the last 4 weeks * ck elevation not caused by myocardial injury * uncontrolled hypertension at time of randomization
the impact of magnesium supplementation on insulin resistance and secretion in renal transplant recipients

Conditions: Glucose Metabolism; Renal Transplantation

Summary: hypomagnesemia is common in renal transplant recipients and is mainly because of enhanced renal magnesium wasting, caused by immunosuppressive drugs (calcineurin inhibitors). glucose metabolism disorders, including insulin resistance and decreased insulin secretion, are also prevalent post-transplantation and often precede the development of diabetes. as magnesium supplementation has been demonstrated to increase insulin sensitivity in both diabetic and non-diabetic patients, its potential therapeutic supplementation (post-transplantation) deserves further examination. the hypothesis is that magnesium supplementation in renal transplant recipients exerts a beneficial effect on insulin resistance and/or secretion.


Eligibility criteria:
inclusion criteria: * renal transplantation recipients * \> 18 years of age * more than 4 months post-transplantation * hypomagnesemia \< 1,8 milligram/deciliter on 2 consecutive blood samples (laboratory reference interval 1,7 - 2,55 milligram/deciliter) at least 1 month apart. exclusion criteria: * pre-existing diabetes mellitus defined as the intake of anti-diabetic drugs at the time of inclusion * biopsy that proves acute rejection and consecutive treatment with corticosteroid boluses less than 2 months before inclusion * serum creatinine \> 3 milligram/deciliter * active infection (c reactive protein \> 3 milligram/deciliter) * severe hypomagnesemia (\< 1,2 milligram/deciliter) * hypokalemia (\< 3,5 milli-equivalent/liter) * severe hypocalcemia (\< 6,5 milligram/deciliter) * intake of digoxin * intake of magnesium supplementation up to 2 weeks before randomization.
study on the efficacy and safety of enhanced recovery after surgery （eras）in gastrointestinal cancer

Conditions: Enhanced Recovery After Surgery; Gastrointestinal Cancer

Summary: at present, there are more and more reports about enhanced recovery after surgery（eras）in china, but there is no eras treatment standard for gastrointestinal cancer, and there are many factors limiting the development of eras. in recent years, due to the development of minimally invasive technology, the establishment of evidence-based medicine model and the development of mdt, it makes a good solid foundation for the clinical application of eras. the implementation of eras requires the cooperation of surgeons, anesthesia management, nursing, rehabilitation and other teams. as an individualized treatment mode, eras focuses on the optimization of treatment for different individuals in order to acquire the best benefit of patients. therefore, the concept of eras is still in the process of continuous improvement and development in china, hoping to explore the chinese eras clinical pathway for gastrointestinal cancer. the purpose of this study is to optimize the clinical pathway of eras in the perioperative period of gastrointestinal cancer, and to evaluate the effectiveness and safety of eras in gastrointestinal cancer.


Eligibility criteria:
inclusion criteria: * sign the informed consent * preoperative pathology confirmed gastric cancer or colorectal cancer * age: 18-70 years, men or women * according to nccn guidelines, it is not stage iv tumor * perform radical gastrectomy or radical colon cancer surgery (cme) or radical rectal cancer surgery (tme); * asa i-iii * receive no radiotherapy or chemotherapy before operation * the subjects can describe the symptoms objectively and keep the follow-up plan exclusion criteria: * preoperative pathology confirmed no gastric cancer / no colorectal cancer (such as rectal neuroendocrine tumor, lymphoma, etc.) * stage iv or radical resection can't be performed * emergency operation * can't cooperate with clinical data collection * general condition is intolerable to operation * serious diseases, including heart function ≥ level ii, respiratory function insufficiency, liver and kidney function insufficiency, and blood system diseases * patients participate in other clinical trials at the same time * pregnant or perinatal women * other malignant tumors * history of mental illness * had a history of severe trauma within 4 weeks before admission * less than 6 months after other level 4 operations
3d-printing and acces to tele rehabilitation

Conditions: Orthopedic Disorder

Summary: this study will investigate whether 3d printing of orthoses (night splints and afo/kafo for walking, further named as dynamic afo/kafo) for the lower limbs can help to improve the limited accessibility to orthopaedic devices in developing countries. the 3d printed orthoses will be assessed for effectiveness, cost and feasibility. measurement and manufacture of the orthoses is also supported remotely via video conferencing.

specifically, the study is being conducted in 3 west african countries: togo, niger and mali. a total of 4 orthopaedic centres are involved, whereby an equal number of patients are recruited everywhere. there are 2 groups of patients, those who need a (knee) ankle-foot orthosis to move around (dynamic afo/kafo) and those who need a night splint to correct the ankle or knee position. all patients in the study will have a treatment route involving fitting a new traditional orthosis and a new 3d printed orthosis. the order of application of both treatments will be randomised in a crossover design. patients will be measured at baseline after the first treatment period (3 weeks) and after the second treatment period (6 weeks). the primary outcome measures are different for both groups of patients: the walking speed when performing the 10-metre walk test in the patients wearing the dynamic afo/kafo, and the measured angle (of knee or ankle) in the patients wearing a night splint.

Eligibility criteria:
inclusion criteria: * pathology: foot stance abnormality * both unilateral and bilateral orthoses are included * pathology: genu varum exclusion criteria: * patient is already wearing a night splint * the patient cannot stand upright * the patient is pregnant

Keywords: lower limb
cardiac radiotherapy for ventricular tachycardia ii

Conditions: Ventricular Tachycardia (VT)

Summary: steoreotactic therapy radioablation has become a standard of care option for patients with therapy-refractory ventricular tachycardia, yet long-term outcome is lacking. the objective of this study is to evaluate the long-term outcomes, both efficacy and safety, after star in patients with therapy-refractory ventricular tachycardia.


Eligibility criteria:
inclusion criteria: * eligible for star for therapy-refractory vt based on a multidisciplinary discussion * ability to give a written informed consent and willingness to return for follow-up exclusion criteria: * contra-indications for star, including pregnancy or breastfeeding, previous radiotherapy with cardiac involvement, life-expectancy \< 6 months in the absence of vt * any condition that is deemed a contraindication in the judgment of the investigators

Keywords: ventricular tachycardia star stereotactic radiotherapy
transcranial direct current stimulation of the temporal cortex in survivors of childhood acute lymphoblastic leukemia (all)

Conditions: Acute Lymphoblastic Leukemia; Transcranial Direct Current Stimulation; Executive Dysfunction

Summary: brief overview: children and adolescents diagnosed with cancer will experience problems with learning, memory and attention during and after completing their cancer therapy. there are many factors that contribute to this problem, but investigators have recently identified that chemotherapy agents used in treating acute lymphoblastic leukemia (all) may disrupt normal brain development. a novel device has been developed that may help correct this disruption. direct current stimulation (dcs) uses a very low level of constant electrical current to stimulate specific parts of the brain. it has been used in patients with stroke to great benefit. our study at st. jude children's research hospital is designed to see if this technique will benefit survivors of childhood cancer. specifically, investigators wish to see if stimulating one part of the brain gives a greater benefit than stimulating another part of the brain. primary objective evaluate the feasibility of conducting repeated on-site transcranial direct current stimulation (tdcs) in children who are long-term survivors of secondary objectives * to estimate the potential efficacy for powering a future larger study using tdcs to improve cognitive performance in children by suppressing over connected neural hubs in long-term survivors of childhood all. * to compare the performance of anodal stimulation of the frontal lobe to cathodal suppression of the superior temporal lobe on cognitive performance.

participants will be randomly assigned to one of three intervention arms. two brief stimulation periods will be conducted on day one. one brief stimulation will be scheduled in the morning and a second brief stimulation will be scheduled in the afternoon. a final stimulation will be conducted on day two. direct current stimulation will be applied for 20 minutes for each stimulation period. brief neurocognitive testing will be conducted during each stimulation session.

Eligibility criteria:
inclusion criteria: * all survivors who received chemotherapy-only treatment and are enrolled in sjlife. * 8-17 years old. * history of executive function, processing speed and/or memory impairment documented as a score \< 10th percentile of the age adjusted z-score. * participants able to speak and understand the english language. exclusion criteria: * survivors who received cranial radiation. * survivors with a full-scale iq \< 70. * pregnant, history of migraines, epilepsy or traumatic brain injury. * have a scalp or skin condition (e.g., psoriasis or eczema), metallic implants (except for dental fillings or caps) or retained metal fragments. * history of neurologic condition or genetic disorder associated with neurocognitive impairment unrelated to cancer diagnosis or treatment. * not fluent in english. * taking a psychoactive drug or stimulant.
a multicenter randomized controlled study of pulse magnetotherapy combined medication in anxiety combined with insomnia

Conditions: Anxiety Disorder; Insomnia

Summary: the goal of this clinical trial is to explore the therapeutic effect of pulse magnetic therapy system combined with drug therapy on patients with anxiety and insomnia. the main questions it aims to answer are: 1. whether the pulse magnetic therapy system is benefit on improving insomnia in anxiety patients. 2. this improvement is not due to the placement of the instrument。 participants will accept pulse magnetic therapy (stimulation/sham stimulation) and accept scale evaluation before and after treatment. researchers will compare the pulse magnetic stimulation group, sham stimulation group and healthy controls to see if the pulse magnetic stimulation do effect on insomnia of anxiety patients.

insomnia is the most common symptom of anxiety disorder, which has an important impact on the prognosis of anxiety. pulse magnetic therapy system, with its advantages of compact, convenient, easy to carry, and not limited by the scene and time, has gradually become a common tool for sleep monitoring and treatment. this study is a multicenter randomized controlled design, including 150 cases in the pulse magnetic stimulation+drug treatment group, 150 cases in the sham pulse magnetic stimulation+drug treatment group and 100 healthy controls. before and after treatment, the patients were comprehensively measured and evaluated with insomnia severity index (isi), hamilton depression rating scale 17 (hamd), hamilton anxiety rating scale (hama), pittsburgh sleep quality index (psqi), self-rating sleep scale (ssrs), self-rating symptom scale 90 (scl-90), quality of life scale (sf-36), and treatment adverse reaction scale (tess), and sleep monitoring was conducted at the same time, to explore the therapeutic effect of pulse magnetic therapy system detector combined with drug therapy on patients with anxiety and insomnia.

Eligibility criteria:
inclusion criteria: 1. patients who met the diagnostic criteria for anxiety disorder in the diagnostic and statistical manual of mental disorders (fifth edition; dsm-5) and were accompanied by insomnia with 14 \ 7 ; 2. education level is unlimited; 3. age: 18-55 years old. exclusion criteria: 1. have bipolar disorder, schizophrenia, depression and other mental diseases; 2. have a clear history of head trauma, alcoholism, brain tumors, diabetes, hypertension, and serious primary heart, liver, kidney, and blood system diseases; 3. at present, patients with sleep disorders are being treated by other means besides drugs; 4. pregnant and lactating women; 5. have a history of seizures or strong positive family history of epilepsy; 6. implantation of cardiac pacemaker; 7. those receiving deep brain stimulation treatment; 8. there are metal or magnetic implants in the body (including but not limited to the brain); 9. participated in clinical trials of other drugs and medical devices in recent 3 months; 10. other researchers believe that they do not meet the conditions for inclusion.

Keywords: anxiety insomnia pulse magnetotherapy
experience of lock down related to the covid-19 epidemic and its impact on the project of parenthood

Conditions: Assisted Reproduction

Summary: observational, descriptive, cross-sectional, monocentric study, this study is proposed to all couples followed in assisted reproduction and cecos nord for whom the protocols were stopped when they entered into confinement related to the covid-19 epidemic on 13 march 2020.


Eligibility criteria:
inclusion criteria: * couples followed up in assisted reproduction and cecos nord * the cessation of assistance reproduction protocols related to the covid-19 outbreak on march 13, 2020. * acceptance of teleconsultation exclusion criteria: * individuals refusing to participate in the study during the teleconsultation with the referring practitioner. i- ndividuals who do not respond to the questionnaire
headache inducing characteristics and possible changes in cerebral blood flow after administration of pge2

Conditions: Headache; Migraine

Summary: before, during and after intravenous administration of pge2 we score/measure headache, rcbf, blood flow in the middle cerebral artery and diameter of superficial temporal artery and correlate that to known pathophysiology of headache to see if pge2 is involved in headache pathophysiology.


Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * primary headache, headache on the day of the investigation, hypertension, hypotension, pregnant/nursing, daily intake of medication (except oral contraceptives), cardiovascular or cns disease, drug/alcohol abuse, psychiatric disease
evaluation of drug activity in women with breast cancer and no previous herceptin treatment

Conditions: Breast Neoplasm

Summary: to compare the activity of azd8931 against placebo on the cell markers in cancer tumours

a randomised double-blind placebo-controlled multicentre phase i study to assess the biological activity of azd8931 in patients with early breast cancer who are ineligible for treatment with trastuzumab as defined by ihc status

Eligibility criteria:
inclusion criteria: * females aged 18 or older early stage breast cancer and planned surgery * ineligible for trastuzumab (herceptin) treatment as per local guidelines * world health organisation performance status of 0 to 1 tumour size amenable to obtaining adequate biopsies pre dosing. exclusion criteria: * eligible for trastuzumab (herceptin) treatment known sensitivity to azd8931, its excipients or drugs in its class; * including oral tyrosine kinase inhibitors history of eye conditions e.g. previous injury within 3 months or clinically significant eye disease * concurrent malignancy unable to discontinue medication or herbal supplement known to inhibit cyp3a4 or cyp2d6

Keywords: breast neoplasm breast cancer breast tumour cancer of breast cancer of the breast
a study of her2 tumor vaccine in patients with her-2 positive gastric/gej adenocarcinoma esophagogastric

Conditions: Adenocarcinoma - GEJ; Adenocarcinoma of the Stomach

Summary: this is a single-arm, open-label, clinical study to evaluate the safety of her2 tumor vaccine injection alone/in combination with standard of care chemotherapy in patients with her2/neu overexpressing gastric or gastroesophageal junction (gej) adenocarcinoma. the purpose of this study is to evaluate the safety and tolerability, antitumor activity, the immunoreactivity, pharmacokinetics and of her2 tumor vaccine.


Eligibility criteria:
inclusion criteria: * male or female aged ≥ 18 years; * metastatic gastric or gej adenocarcinoma, or locally advanced disease not amenable to surgical resection; * her2/neu overexpression (3+ by immunohistochemistry (ihc) or if ihc 2+ confirmed by fluorescent in situ hybridization \[fish\]; * ecog score of 0 \~ 2; * adequate bone marrow, hepatic and renal and coagulation function; * women of childbearing age who have a negative pregnancy test within 7 days before treatment. female patients of childbearing age, and male patients with partners of childbearing age must agree to use at least one medically recognized contraceptive method during study treatment and within at least 6 months after the last dose of investigational drug; * voluntarily participated in this study, signed the informed； exclusion criteria: * continuous systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of study treatment. inhaled or topical steroids and physiological replacement doses of up to 10 mg daily prednisone equivalents are permitted in the absence of active auto-immune disease； * subjects who have had major surgery within 4 weeks before her2 tumor vaccine administration * subjects who have received anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, etc within 5 elimination half-life prior first dose of her2 tumor vaccine treatment; * subjects with known brain metastasis and/or clinically history tumor brain of metastasis； * patients with uncontrollable pleural effusion, abdominal effusion and pericardial effusion; * active infection requiring treatment. hiv, hcv, syphilis, cmv, ebv infected patients; patients with active hbv replication * other conditions that the investigator assessed as ineligible for inclusion.
hemodynamic indices predictive of a beneficial response to fluid expansion in case of hemodynamic failure after cardiac surgery with altered preoperative ejection fraction (lvef≤45%)

Conditions: Ventricular Dysfunction

Summary: low cardiac output syndrome occurs frequently after cardiac surgery, especially when pre-operative lvef is altered (lvef≤45%). the correction of hemodynamic failure requires adapted treatments: fluid expansion and/or inotropic or vasoactive drugs. predictive indices of a response to fluid challenge may allow an earlier hemodynamic optimization, which has not been showed until now when lvef is altered.


Eligibility criteria:
inclusion criteria: * patients \>18 years old in the immediate post-operative period after cardiac surgery * asa 1 - 3 * pre-operative lvef≤45% * sedated with ramsay score: 6 * mechanically ventilated with tidal volume at 8ml/kg, peep at 0mmhg, i/eat 0,5 * with hemodynamic failure: sap≤90mmhg and/or inotropic or vasoactive drug started in the operating room and/or clinical sign of shock and/or ci ≤2,3l/min/m2 * affiliation to health insurance * consent form signed exclusion criteria: * cardiac arrhythmia: frequent atrial or ventricular extra systoles, atrial fibrillation * intracardiac shunt * weight less than 50 kg * history of central nervous system illness * pulmonary oedema (clinical and/or radiological and/or wedge pressure\>18mmhg) * right ventricular failure suspected (cvp\> wedge pressure) or diagnosed (trans thoracic and/or transesophageal echocardiography) * acute kidney injury with oligoanuria * severe post operative bleeding (chest tubes volume of \>200ml/h for 3 hours or more) * severe hypoxia (pao2/fio2\< 100) * administrative control (patient under guardianship or curatorship)